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ABSTRACT
Antibacterial fluoroquinolones trap a cleavage
complex of gyrase and topoisomerase (topo) IV
inducing site-specific DNA breakage within a bent
DNA gate engaged in DNA transport. Despite its im-
portance for drug action and in revealing potential
sites of topoisomerase catalysis, the mechanism of
DNA selectivity is poorly understood. To explore its
functional basis, we generated mutant versions
of the strongly cleaved E-site and used a novel
competitive assay to examine their gemifloxacin-
mediated DNA breakage by Streptococcus
pneumoniae topo IV and gyrase. Parallel studies of
Ca2+-induced cleavage distinguished ‘intrinsic rec-
ognition’ of DNA cleavage sites by topo IV from
drug-induced preferences. Analysis revealed
strong enzyme-determined requirements for 4G,
2A and 1T bases preceding the breakage site
(between 1 and+1) and enzyme-unique or degen-
erate determinants at 3, plus drug-specific prefer-
ences at+2/+3 and for+1 purines associated with
drug intercalation. Similar cleavage rules were seen
additionally at the novel V-site identified here
in ColE1-derived plasmids. In concert with DNA
binding data, our results provide functional
evidence for DNA, enzyme and drug contributions
to DNA cleavage at the gate, suggest a mechanism
for DNA discrimination involving enzyme-induced
DNA bending/helix distortion and cleavage
complex stabilization and advance understanding
of fluoroquinolones as important cleavage-
enhancing therapeutics.
INTRODUCTION
Type II DNA topoisomerases are biologically essential
enzymes that mediate the ATP-dependent gating of one
DNA duplex through a transient double-stranded break
introduced in another DNA duplex (1–3). They function
to regulate chromosomal DNA supercoiling and to
remove supercoils and catenanes produced variously in
DNA replication, transcription and recombination.
Eukaryotes express the homodimeric topoisomerase II
found as alpha and beta isoforms in mammalian cells
(4). Topoisomerase (topo) IV and DNA gyrase are the
bacterial type II topoisomerases each performing
specialized cellular roles (5–8). Topo IV promotes the un-
linking of catenated daughter chromosomes to allow their
segregation at cell division, whereas gyrase introduces
negative supercoils into DNA, facilitating replication
fork movement and allowing control of gene expression
(9). For each enzyme, the active complex is a tetramer
composed of two copies both of topo IV ParC and ParE
subunits or of gyrase GyrA and GyrB proteins (2). The
subunits have a modular design with the closely related
N-terminal regions of the ParC and GyrA proteins
constituting the DNA breakage–reunion domains and
the divergent C-terminal ends directing inter- and intra-
molecular DNA transport, respectively (2,8,10,11). The
highly conserved ParE and GyrB subunits have N- and
C-terminal domains comprising, respectively, the ATPase
site that directs conformational changes in the complex
and the TOPRIM fold that binds Mg2+ ions essential
for reversible DNA breakage (2,10–15).
In common with other type II topoisomerases, topo IV
and gyrase transiently break DNA through the formation
of a covalent enzyme–DNA intermediate known as the
‘cleavage complex’ (11,16). The DNA in this complex
(sometimes termed the gate-DNA or G-segment) exhibits
a 4-bp staggered break involving the covalent linkage of
ParC (GyrA) subunits, one to each 50-phosphate end via
active-site tyrosine residues. The cleavage complex allows
DNA transport through the gate-DNA coordinated with
the sequential opening and closure of other enzyme gates
formed by the N-terminal ends of ParE (GyrB) and within
the ParC (GyrA) subunits. DNA breakage is readily
reversed by nucleophilic attack of the 30OH ends on the
phosphotyrosyl links regenerating the intact DNA
backbone. Indeed, the DNA breakage–reunion equilib-
rium of type II topoisomerases lies well over to the
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sealed state avoiding the inadvertant release of lethal
double-stranded DNA breaks (11,16).
A variety of clinically important antibacterial and
anticancer drugs inhibit type II topoisomerases, sustaining
interest in these enzymes as therapeutic targets (17,18).
Anticancer agents such as etoposide target eukaryotic
topo II, whereas antibacterial ﬂuoroquinolones, e.g.
gemiﬂoxacin and levoﬂoxacin, target topo IV and/or
gyrase (Figure 1). The drugs interfere with DNA religation
to stabilize a topoisomerase cleavage complex, which
cellular processes convert into a cytotoxic lesion,
possibly a double-stranded DNA break (19). Drug-
arrested complexes are readily detected in vivo and
in vitro by denaturation with sodium dodecyl sulphate
(SDS), releasing double-stranded DNA breaks at speciﬁc
sites (20,21). Although anticancer drug-promoted DNA
cleavage has been extensively studied for eukaryotic
topo II (22), much less is known about ﬂuoroquinolone-
mediated breakage by bacterial type II topoisomerases.
Consensus cleavage sequences have been derived for
topo IV and gyrase from Streptococcus pneumoniae in
the presence of gemiﬂoxacin and other clinically import-
ant quinolones used against this Gram-positive pathogen
(Figure 1) (23). Using stringent statistical criteria, these
sequences were G(G/c)(A/t)a*GNNCt(T/a)N(C/a) and
GN4G(G/c)(A/c)G*GNNCtTN(C/a) for topo IV and
gyrase, respectively (where the asterisk indicates the
cleavage site between 1 and +1 bases, capital letter
denotes preferred base, lower case letter denotes disfa-
voured base and N, no base preference). A second
analysis using SV40 template DNA instead of pneumococ-
cal DNA and weaker statistical stringency gave a different
outcome, notably a preference for GGGCCC at positions
1 to+5 possibly reﬂecting the greater representation of
GGG and CCC traits in SV40 DNA (24). Template bias,
enzyme and drug levels, inclusion of weak sites, averaging
across potentially different binding modes and the strin-
gency adopted can all affect the derived consensus.
Moreover, consensus data leave open a number of un-
answered questions. First, what constitutes an ‘optimal’
cleavage site? Second, do gyrase and topo IV have the
same or different cleavage requirements? Third, are all
consensus elements necessary for efﬁcient cleavage?
Fourth, what distinguishes ‘cleavable’ and ‘uncleavable’
sequences? Finally, how are sequences discriminated and
what molecular interactions are involved?
To address these questions, we have used the comple-
mentary approach of manipulating strongly cleaved sites
by systematic mutagenesis. Cleavage-enhancing, -disrupt-
ing and -neutral changes deﬁne the contacts needed for
efﬁcient DNA breakage. Bacteriophage T4 topoisomerase
provides the best example to date, but this specialized
enzyme more closely resembles a eukaryotic type II topo-
isomerase, for example, in requiring anticancer drugs for
efﬁcient DNA cleavage (25). Few studies have focused on
prokaryotic type II topoisomerases per se. An early inves-
tigation of DNA cleavage selectivity by Escherichia coli
gyrase was limited in scope by the restricted mutagenesis
techniques and poor potency of the quinolones then in
use (26). Furthermore, previous studies have lacked
high-resolution X-ray structure information needed for
mechanistic analysis.
Here we establish the functional determinants for quin-
olone-induced DNA breakage by pneumococcal topo IV
and gyrase at the strongly cleaved E- and (newly dis-
covered) V-sites, the ﬁrst systematic analysis for any bac-
terial type II enzyme. To facilitate analysis, we developed
a powerful new assay that allows rapid screening of
multiple sites in competition. By overlaying the sequence
preferences we observed in Ca2+-induced DNA breakage
by topo IV, we could distinguish enzyme versus drug-
speciﬁc determinants. Guided by recent E-site-topo IV
structures revealing two quinolones intercalated at a
highly bent cleaved DNA gate (27,28), we propose a
model that accounts for DNA selectivity in cleavage.
MATERIALS AND METHODS
Bacterial strains, reagents and plasmids
Escherichia coli XL1-Blue supercompetent cells and ‘One
Shot TOP10’ chemically competent E. coli were obtained
from Stratagene and Invitrogen. Escherichia coli strain
BL21 (DE3) pLysS was obtained from Novagen.
Oligonucleotide primers were synthesized by Sigma and
Metabion. Gemiﬂoxacin and levoﬂoxacin were from
GlaxoSmithKline, Harlow, UK and from McNeil-Ortho,
respectively. Other quinolones were from our laboratory
stocks. The 4–12% polyacrylamide Tris-Borate-EDTA
(TBE) gels were from Invitrogen. Ni-NTA resin was
from Qiagen. SYBR Green I Nucleic Acid Gel Stain
was obtained from Lonza, Slough, UK. BIOTAQTM
DNA polymerase was from Bioline and Pfu DNA poly-
merase was from Stratagene. Plasmid pXP1, carrying a
4.3-kb HindIII fragment of the S. pneumoniae parE-parC
locus (29) was from our laboratory strain collection.
Plasmid vector pCR2.1 TOPO was supplied by
Invitrogen. Supercoiled pBR322 was from New England
BioLabs. [g-33P]ATP (3000Ci/mmol) was purchased from
MP Biomedicals NV/SA in 9.25 MBq amounts.
Recombinant topo IV and gyrase subunits
Streptococcus pneumoniae ParC, ParE, GyrA and GyrB
subunits were expressed as His-tagged proteins in E. coli
BL21 (DE3) pLysS and puriﬁed to >95% homogeneity
as previously described (30,31).
Figure 1. Structures of gemiﬂoxacin and levoﬂoxacin, two anti-
pneumococcal ﬂuoroquinolones.
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Mutagenesis of the topo IV E- and V-sites
The E-site from the S. pneumoniae parE gene contained in a
256-bp polymerase chain reaction (PCR) product was
ampliﬁed from plasmid pXP1 (29) by PCR using
BIOTAQTM DNA polymerase with forward primer
E-FOR, 50 GATTCTCAGATAACATTCTA and reverse
primer E-REV, 50 TAGGGGGCTTCCTAGTTTA. The
PCR reaction (50ml) contained 67mM Tris–HCl (pH 8.8
at 25C), 16mM (NH4)2SO4, 0.01% stabilizer, 1.5ml of
50mM MgCl2, 0.5ml of 100mM dNTP mix, 125 ng each
of forward and reverse primers, 5 ng of DNA template and
BIOTAQTM polymerase (5 units). Conditions for ampliﬁ-
cation were as follows: denaturation at 95C for 30 s, an-
nealing at 53C for 35 s and extension at 74C for 1min,
30 cycles. The PCR product was puriﬁed on a QIAquick
spin column (Qiagen) according to the manufacturer’s in-
structions, ligated into the pCR2.1 TOPO vector and used
to transform competent E. coli TOP10 cells. Recombinant
clones were selected by plating on agar plates containing
ampicillin. Individual colonies were picked and 5ml of
overnight cultures were used to purify plasmid DNA
using the QIAprep Miniprep method according to the
manufacturer’s instructions. DNA sequence analysis con-
ﬁrmed the cloning of the correct sequence and one plasmid
clone, pEA1, was used for subsequent studies.
Plasmid pEA1 was used as a template to generate a
variety of mutated versions of the E-site using the
QuikChange site-directed mutagenesis kit (Stratagene)
and complementary 42-mers viz 50TACCAAGGTCATG
AATGACTATGCACGTAAAACAGGTCTTC (top
strand) and 50GAAGACCTGTTTTACGTGCATAGTC
ATTCATGACCTTGGTA (bottom strand) bearing
appropriately placed mutations in the E-site sequence
underlined. Mutated pEA1 plasmids were recovered and
the presence of the correct mutations was veriﬁed by DNA
sequence analysis of the 256-bp E-site insert.
Mutations at the V-site were introduced similarly using
plasmid pEA1 (EM4C) (bearing 4C/+8G changes at the
E-site) as template and two pairs of mutagenic primers:
VM4C-F (50CACTCAAAGGCGGTACTACGGTTATCGA
CAGAATCAGGGGAT) and VM4C-R (50ATCCCCTGATT
CTGTCGATAACCGTAGTACCGCCTTTGAGTG) spe-
cifying 4C/+8G changes (bold underlined), and VM2T-F
(50CACTCAAAGGCGGTAATTCGGTTAACCACAGAA
TCAGGGGAT) and VM2T-R (50ATCCCCTGATTCTGTG
GTTAACCGAATTACCGCCTTTGAGTG) carrying 2T/
+6A changes. The mutant plasmids were recovered and V-site
mutations were conﬁrmed by DNA sequence analysis.
DNA cleavage assays
A variety of DNA substrates was used in cleavage reactions
with recombinant pneumococcal topo IV and gyrase
including PCR products and linear plasmid DNA. In
initial studies, wild-type (wt) and mutant E-site substrates
were ampliﬁed by PCR as 256-bp fragments using pEA1 or
its mutant derivatives as template with BIOTAQTM poly-
merase and E-FOR and E-REV primers under the condi-
tions described above. DNAproducts were recovered using
QIAquick PCR puriﬁcation columns and the DNA con-
centration and purity was determined spectrophotometric-
ally. Each PCR product (0.2 mg) was incubated with
S. pneumoniae ParC/GyrA (0.45 mg) and ParE/GyrB
(0.85 mg) in the presence or absence of quinolones. Topo
IV reaction buffer contained 40mM Tris–HCl, pH 7.5,
6mMMgCl2, 10mMDTT, 200mM potassium glutamate,
and 50 mg/ml bovine serum albumin (BSA) in total volume
of 20 ml. Gyrase buffer comprised 35mMTris–HCl, pH 7.5,
6mM MgCl2, 1.8mM spermidine, 24mM KCl, 5mM
DTT, 36 mg/ml BSA, and 6.5% glycerol (w/v). After
incubation at 37C for 1 h, SDS and proteinase K were
added to ﬁnal concentrations of 1% and 100mg/ml.
Incubation was continued for another hour at 42C to
digest ParC/GyrA protein covalently bound to DNA.
Samples were run in 4–12% gradient polyacrylamide gels
in TBE buffer, visualized by staining with ethidium
bromide and photographed under UV illumination using
a Biomolecular Imager (Fujiﬁlm).
For competitive cleavage assays, wt and mutant E-site
PCR products were ampliﬁed as 276-bp and as 256-, 236-
and 216-bp products using forward primer E-FOR and
the reverse primers ER-20A (50AAAAAAAAAAAAAA
AAAAAATAGGGGGCTTCCTAGTTTA), EREV (50G
ATTCTCAGATAACATTCTA), ER2 (50-CCTTGGTCT
GTCCTTCAAAC) and ER4 (50-TGCAAGTGTTCTTC
AGGAAC), respectively. PCR products were puriﬁed on
spin columns and quantiﬁed as described previously.
Cleavage reactions with topo IV were carried out as
above with gemiﬂoxacin or levoﬂoxacin in the absence
or presence of 1mM ATP using a mixture of 100 ng
each of the wt E-site and three different mutant E-sites
present on 276-, 256-, 236- and 216-bp PCR fragments,
respectively. After addition of SDS and incubation with
proteinase K, substrates and cleavage products were
separated on 4–12% polyacrylamide TBE gels as above.
After staining with ethidium bromide or SYBR Green,
DNA bands were photographed and quantitated using
Fuji Multi Gauge software.
Plasmid pEA1 and its derivatives bearing mutated
E- and V-sites were linearized with ScaI and used as sub-
strates for DNA cleavage by topo IV. The cleavage assay
contained linear plasmid DNA (450 ng), ParC (450 ng),
ParE (850 ng), 6mM MgCl2 and gemiﬂoxacin at 2.5 mM
contained in the same topo IV cleavage buffer used for
cleavage of E-site PCR fragments. Reactions were
incubated at 37C for l h, and following SDS and protein-
ase K treatment, DNA products were separated by elec-
trophoresis in a 1.2% agarose gel run in TBE. DNA bands
were visualized by staining with ethidium bromide and
photographed under UV light.
For calcium cleavage experiments, quinolone and Mg2+
were omitted and substituted with 32mM CaCl2.
DNA sequence analysis of V- and E-site cleavage
Gemiﬂoxacin-mediated cleavage of Nco-I linearized pEA1
revealed a second major cleavage site, the V-site, that
produced 1.9- and 2.2-kb cleavage fragments. Use of
other restriction fragments located the site just outside
the replication origin region in the vector sequence of
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pCR2.1 TOPO. The V-site was found to reside on a 457-
bp fragment ampliﬁed from pEA1 plasmid by PCR using
the BIOTAQTM polymerase enzyme and oligonucleotide
primers V1 (5
0AAAACGCCAGCAACGCGGCCT) and
V2 (5
0AGGGCGAATTCCAGCACA), and topo IV
cleavage assays allowed mapping to a 50- to 100-bp
region. Use of a third oligo V3 (5
0 GTATTGGGCGCTC
TTCCGCT) in conjunction with primer V1 ampliﬁed a
195-bp V-site PCR product that was suitable for
high-resolution sequence analysis.
Primers V1 and V3 (10 pmol) were 5
0-end-labelled by
incubation with [g-33P]ATP (10 pmol) and T4 polynucleo-
tide kinase (5U) in a total volume of 10 ml. Reaction was
conducted at 37 C and then the kinase was heat
inactivated at 90C for 3min and the DNA was recovered
and puriﬁed on spin columns. Labelled primers were used
in PCR to produce cycle sequencing chain termination
ladders and to amplify the 195-bp V-site PCR fragment
from pCR 2.1 TOPO uniquely end-labelled for cleavage
analysis. To label one or other strand, PCR was carried
out with 10 pmol of one 50-end 33P-labelled primer and an
equal amount of unlabelled reverse primer (V1 and V3
extend the top and bottom strands, respectively). DNA
fragments were puriﬁed on spin columns.
Cleavage of V-site DNA end-labelled in the top or
bottom strand (0.2 pmol) was carried out at 37C for
1 h with ParC (0.45 mg) and ParE (1.7 mg) in 35mM
Tris–HCl, pH 7.5, 6mM MgCl2, 24mM KCl, 5mM
DTT, 6.5% glycerol and 50 mg/ml BSA. Gemiﬂoxacin
was included at 10 mM. Reactions were stopped by
addition of SDS to 1%, and after incubation with protein-
ase K, DNA products were precipitated with ethanol.
Samples were resuspended in 40 ml of loading buffer
(95% formamide, 10mM NaOH, 0.25% bromophenol
blue, 0.25% xylene cyanol), heated at 90C for 2–4min
and separated by electrophoresis in an 8% denaturing
urea-polyacrylamide gel. Gels were ﬁxed in 10% v/v
acetic acid and 10% v/v methanol, dried under vacuum
on to Whatman 3MM ﬁlter paper, exposed to a
PhosphorImager screen and visualized using software
supplied by Amersham Biosciences and ImageQuant.
The position of the cleavage site on the labelled DNA
strand was determined by comparison of cleavage
fragment mobility with a dideoxy sequencing ladder run
alongside that had been generated by V1- and V3-labelled
primer extension (using the fmol DNA cycle sequencing
kit) and the same labelled primer utilized in making the
end-labelled DNA substrate.
A similar approach was adopted to determine the sites
of cleavage at mutant E-sites using 256-bp PCR products
labelled on one strand by using 50-end 33P-labelled E-FOR
and unlabelled E-REV primers.
Inhibition of pBR322 cleavage by short duplex DNAs
Wild-type and mutant E-sites were tested for their ability
to act as inhibitors of topo IV cleavage of supercoiled
plasmid pBR322. The wt E-site duplex was generated by
annealing highly puriﬁed complementary 34-mer oligo-
nucleotides: 50-ACCAAGGTCATGAATGACTA
TGCACG TAA AACAG and 50-CTGTTTTACGTGCA
TAGTCATTCATGACCTTGGT. Mutant E-sites M2C,
M4C and M1A were produced from complementary
oligonucleotides bearing the appropriate symmetrical
base changes in the gate region (underlined). In the
annealing protocol, 2.5 nmol of each oligonucleotide in
reaction buffer (50 ml) containing 10mM Tris–HCl,
10mM MgCl2 and 50mM NaCl was heated at 65
C for
30min in a PCR machine and then cooled slowly (2C per
min) to room temperature. The concentration of each
duplex DNA was determined by Nanodrop before inclu-
sion in a standard cleavage assay containing supercoiled
pBR322 (400 ng), topo IV and 0.17 mM gemiﬂoxacin.
Cleavage products were separated and analysed by
electrophoresis in a 1% agarose gel.
RESULTS
Functional determinants of quinolone-promoted topo
IV-DNA cleavage revealed by a novel competitive assay
To investigate the biochemical requirements for DNA
cleavage by bacterial type II topoisomerases, we used
the E-site present in the S. pneumoniae parE gene (23). It
is the strongest topo IV site within an 8-kb region of the
pneumococcal chromosome and displays a high degree of
2-fold symmetry with 4G, 2A and 1T present on each
strand corresponding to+8C,+6T and+5A on the com-
plementary strand (Figure 2A). The E-site was ampliﬁed
as a 256-bp PCR fragment and cloned into vector pCR2.1
TOPO to yield plasmid pEA1 (Figure 2B), which was used
as a template in oligonucleotide-directed mutagenesis to
introduce a variety of symmetric pairwise and single mu-
tations into the 4 to+8 region (Figure 2C). The mutant
plasmids were used to develop a new competitive assay in
which wt and mutant E-sites (m1, m2 and m3) contained,
respectively, on 276-, 256-, 236- and 216-bp PCR products
(ampliﬁed from pEA1 and its mutants), are mixed in equal
weight, cleaved in parallel by topo IV in the presence of
ﬂuoroquinolone and the signature 176-, 156-, 136- and
116-bp cleavage products (plus the 100-bp partner
fragment) are separated and detected by gradient poly-
acrylamide gel electrophoresis (Figure 3A). By providing
a choice of independent substrates, the assay compares
breakage at mutant sites with that of the wt site internal
control and requires only a few gel lanes to display the full
cleavage repertoire.
Figure 3B displays representative results for topo IV
cleavage promoted by gemiﬂoxacin. Panel (a) shows a
control experiment in which four starting substrates each
bearing the wt E-site were mixed with topo IV in the
absence () or presence (+) of drug, and cleavage was
revealed by denaturation with SDS. Following incubation
with proteinase K (to remove covalently bound ParC),
DNA products were separated and visualized. The gel
system nicely resolves all four DNA substrates as well as
the expected 176-, 156-, 136-, 116- and 100-bp cleavage
products. Appropriate mixes of wt 276-bp substrate and
mutant E-site substrates were used in panels (b)-(h) to
examine the effects of mutations at each position in the
4 to+8 region. Cleavage by topo IV was detected only in
the presence of gemiﬂoxacin (cf – and + lanes in each
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panel). From panels (b)-(d), it is clear that any pairwise
change of the symmetric wt 4G/+8C, 2A/+6T and
1T/+5A nucleotides resulted in the absence or marked
reduction in the yield of signature cleavage products: in
each case, only the wt E-site was strongly cleaved,
producing the prominent 176-bp product. By contrast,
all base combinations at 3/+7 positions produced wt
levels of cleavage product except A/T for which the yield
of 116-bp product was drastically reduced (panels (e) and
(f)). Similarly for+1/+4 positions, purine/pyrimidine pairs
G/T, G/C and A/T favoured efﬁcient cleavage, whereas C/
G blocked cleavage as shown in panel (g). Lastly, panel (h)
indicated selectivity at the+2/+3 positions with the A/C
and A/T combinations favoured, and T/A and C/G disfa-
voured. Inclusion of ATP (at 1mM) did not affect
outcomes (results not shown).
Product bands from two independent sets of competi-
tive cleavage experiments involving 20 mutant sites
covering 4 to +8 positions were scanned and
quantitated, allowing cleavage at the mutant sites to be
compared directly with that of the wt E-site present as
internal control (Table 1). The Table additionally
includes data for the +2/+3 positions not shown in
Figure 3B, revealing cleavage of the +2 G/+3 C mutant
site. Representative data for each base position are pre-
sented in Figure 3C. Scrutiny of each position highlights
the stringent base requirements at 4, 2 and 1 but
greater sequence tolerance at 3, +1 and +2 positions.
Interestingly, most mutations of the E-site sequence
inhibited cleavage, suggesting it is a highly preferred site.
Clearly, the new assay reveals a complex set of functional
requirements for optimal drug-promoted cleavage at
the gate.
Topo IV and gyrase cleavage by single substrate assay
The competitive assay is novel and therefore gemiﬂoxacin-
induced E-site cleavage was checked using the conven-
tional approach in which single substrates (256-bp
PCR products) are cleaved in separate reactions
(Supplementary Figures S1 and S2). Essentially the same
functional rules were uncovered for topo IV although
subtle preferences, e.g. at +1/+4 and +2/+3 were less
obvious under the forcing conditions of the single sub-
strate assay (Supplementary Figure S1). In addition, the
+1 T/+4 A site (not tested in competitive assays) was not
cleaved by topo IV (results not shown). For gyrase,
weaker E-site cleavage precluded competitive analysis.
However, single substrate studies revealed that the func-
tional rules for gyrase overlapped those of topo IV (shared
4G and 2A) but differed in unique preferences (for
3T and 1T) and degenerate preferences at +2/+3
(Supplementary Figure S2). Overall, the competitive
assay was less laborious and easier to quantitate.
Intrinsic versus drug-speciﬁc determinants
It is known that Ca2+ induces topo IV-DNA breakage
at the same sites as seen with Mg2+ (15) (though more
efﬁciently). Therefore, a complete mutational analysis of
cleavage in the presence of Ca2+ should yield information
on the ‘intrinsic recognition’ of a DNA cleavage site
ACCAAGGTCATGAATGACTATGCACGTAAAACAG
TGGTTCCAGTACTTACTGATACGTGCATTTTGTC
+8  +6  +4    +1  -2  -4
-4  -2   +1   +4  +6 +8
E site
kanR
pEA1
4.2kb
ampR
nigiro1f‘nigiro
ScaI, 2438
Plac-lacZV
A
B
C
Figure 2. Structure (A), cloning (B) and mutagenesis (C) of the E-site.
(A) DNA sequence of the 34-bp E-site that is strongly cleaved by
S. pneumoniae topo IV in the presence of gemiﬂoxacin. DNA scission
to generate a staggered double-stranded DNA break occurs at positions
shown by open arrowheads, i.e. between the 1 and+1nt on each strand
within a 12-bp sequence bearing consensus preferences and targeted here
for mutagenesis. (B) Cloning of the E-site to generate plasmid pEA1. The
site contained in a 256-bp PCR fragment (open box) was inserted directly
by topo cloning into vector pCR2.1 TOPO. Filled arrowheads denote
oligonucleotide primers used to amplify the E-site PCR fragment. V
denotes the ‘V-site’, a second location of topo IV cleavage reported in
this study. (C) Mutant E-sites used in this study. The changes indicated
were introduced at the cloned E-site of plasmid pEA1 by oligonucleotide-
directed mutagenesis. The wt E-site sequence and wt bases are denoted
by an asterisk and bold capitals, respectively.
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Figure 3. Analysis of DNA breakage at wt and mutant E-sites using a novel competitive cleavage assay. (A) Schematic diagram showing the basis of
the assay. The wt and mutant (m1, m2 or m3) E-sites are ampliﬁed by PCR from plasmid pEA1 and its mutant variants to generate 276-, 256-, 236-
and 216-bp fragments, respectively. Equal amounts of each of the four substrates are mixed and incubated with topo IV producing signature 176-,
156-, 136- and 116-bp cleavage fragments and a 100-bp product common to all sites. The four substrate and ﬁve cleavage fragments are separated by
electrophoresis allowing the efﬁciency of cleavage at the mutant sites to be compared directly with wt. (B) A representative assay for gemiﬂoxacin-
promoted cleavage by topo IV. Panel (a), all four cleavage substrates (0.1 mg each) carried a wt E-site generating well-separated 176-, 156-, 136- and
116-bp products. Panels (b–h) each used a mix of wt E-site substrate (276-bp) with three mutant site substrates (256-, 236- and 216-bp) carrying
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(continued)
by topo IV. In principle, comparison with quinolone data
would then distinguish enzyme-speciﬁc and drug-depend-
ent contributions to DNA cleavage selectivity. Figure 4
presents a competitive assay of Ca2+-promoted DNA
breakage by topo IV at the E-site and its mutants (lanes
Ca) with the quinolone-reactions run alongside (lanes Q)
[To conﬁrm the results, single substrate assays
(Supplementary Figure S3) were carried out in parallel].
It is evident that nearly all the mutations at 4 to +8
positions that block drug-induced cleavage also inhibited
Ca2+ cleavage (panels B, C, D and F), indicating that, for
most positions, the enzyme plays the key role in cleavage
site selectivity. In particular, the results suggest that
sequence preferences at 4/+8, 3/+7, 2/+6 and 1/
+5 are determined primarily by the enzyme, whereas the
drug is a major determinant of preferences at+1/+4 and
+2/+3. Thus, Ca2+- and quinolone-cleavage proﬁles were
similar for mutants at 4/+8 (panel B), 1/+5 (panel D)
and at 3/+7 (though partial cleavage of the 3 T/+7 A
substrate at an alternative site led to an additional product
band) (panel F). Similarly, E-site mutations at 2A/+6T
block both drug and Ca2+ cleavage, in the latter case
revealing cleavage at an alternative site and producing
the differently sized fragments seen in Figure 3, panel C
and Supplementary Figure S3. Subtle differences in Ca2+
versus quinolone cleavage preferences observed at 4 to
1 positions may arise from known changes in helix con-
formation of the DNA gate occasioned by drug binding
(28). By contrast, enzyme- and drug-mediated cleavage
preferences were different at both+1/+4 and+2/+3 with
+1C/+4G most favoured in the Ca2+-promoted reaction
but strongly disfavoured for gemiﬂoxacin cleavage
(Figure 4, panels G and H, Supplementary Figure S5).
The results show unequivocally that the drug can
override enzyme preferences to confer the different +1/
+4 and +2/+3 base preferences seen in quinolone-
promoted cleavage.
Drug sensing of the cleaved DNA gate
The drug-mediated preference for purines at+1 positions
(Figure 3 and 4) is interesting given that recent X-ray
crystal structures of the topo IV–E-site cleavage complex
reveal two quinolone molecules stacked against the +1
bases (27,28). To examine the sequence preferences of dif-
ferent quinolones, we compared topo IV cleavage of linear
pEA1 plasmid mediated by six ﬂuoroquinolones currently
in clinical use: the antipneumococcal drugs gemiﬂoxacin,
trovaﬂoxacin, moxiﬂoxacin, levoﬂoxacin and sparﬂoxa-
cin, plus ciproﬂoxacin used against Gram-negative patho-
gens (Supplementary Figure S4). All six quinolones
promoted cleavage at a similar spectrum of sites including
the E-site but with efﬁciencies determined by the drug. We
selected the structurally distinct gemiﬂoxacin and levo-
ﬂoxacin (Figure 1) for more detailed comparison using
the competitive assay and the 4, 2 and +1 E-site
mutants used in Figure 3B. Levoﬂoxacin is less potent
than gemiﬂoxacin (32) and therefore a range of different
drug concentrations was used to facilitate comparison at
similar levels of cleavage. Levoﬂoxacin recapitulated the
4 and 2 preferences seen in Figure 3 for gemiﬂoxacin
(results not shown). However, whereas gemiﬂoxacin was
able to promote cleavage of E-sites with a variety of
purine/pyrimidine combinations at +1/+4, levoﬂoxacin
showed a marked preference for the +1G/+4C substrate
yielding predominantly the G/C cleavage product rather
Table 1. Quantitation of cleavage products generated in competitive
assays by quinolone-mediated DNA breakage by topo IV
Position E-site Percent of total cleavage
exp 1 exp 2 mean
4/+8 G/C* 66 70 68
A/T 14 6 10
C/G 1.8 5 3.4
T/A 18.2 19 18.6
3/+7 A/G* 39 25 32
C/G 30 36 33
T/A 25 35 30
A/T 6 4 5
A/G* 37.5 37.7 37.6
G/C 25.3 24.3 24.8
T/A 24.9 24.7 24.8
A/T 12.3 13.3 12.8
2/+6 A/T* 75 85 80
T/A 2.4 4 3.2
C/G 4.5 1.3 2.9
G/C 18.1 9.7 13.9
1/+5 T/A* 58 48 53
A/T 0 0 0
C/G 27 35 31
G/C 15 17 16
+1/+4 G/T* 39.3 37.6 38.45
C/G 13.8 12.1 12.95
G/C 22.6 22.7 22.65
A/T 24.2 27.5 25.85
+2/+3 A/C* 40.3 47.8 44.05
A/T 26.6 24.8 25.7
T/A 19.3 16.8 18.05
C/G 13.8 10.47 12.1
A/C* 54 42 48
G/C 21 35 28
T/A 10 6 8
C/G 15 17 16
Asterisks denote cleavage of wt E-site; exp 1, exp 2 indicate independ-
ent experiments. Bold values are data for the wt E-site.
Figure 3. Continued
changes at 4/+8 (panel (b)), 2/+6 (c), 1/+5 (d), 3/+7 (e and f),+1/+4 (g) and+2/+3 (h). All reactions contained topo IV and 6mM MgCl2 and
were carried out in the absence (±) or presence (+) of 320mM gemiﬂoxacin. Substrates and products were separated by electrophoresis in 4–12%
gradient polyacrylamide gels and DNA bands were stained and photographed. Cleavage at each mutant site compared with the internal E-site
control is indicated by the relative amounts of the cleavage products. Reduced ﬂuorescence of the smaller cleavage products relative to the wt 176-bp
band is largely compensated by the relatively greater number of sites presented per microgram of the smaller substrates. (C) Quantitation of cleavage
products from wt and mutant E-sites in the competitive assay. Dark grey bar denotes the wt product. Data represent the average of two independent
experiments: bars are standard error of the mean.
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than the wt (G/T) product and with little or no breakage
of C/G and A/T sites (Figure 5). These biochemical results
show directly for the ﬁrst time that cleavage preferences at
the+1 positions are modulated by the molecular structure
of the quinolone.
DNA context: a novel plasmid site for topo IV
To investigate the generality of sequence preferences, we
sought to extend cleavage studies to a second site derived
from a different biological and sequence context. By
chance, cleavage of the full-length pEA1 plasmid (rather
than insert PCR products) revealed strong topo IV
cleavage at a second site that mapped to just outside the
replication origin region of the pCR2.1 TOPO vector and
which we termed the ‘V’ or vector site (Supplementary
Figure S4, Figure 2B). PCR products containing the
V-site and 50-33P-labelled on one or other DNA strand
were generated from pEA1 DNA, cleaved by topo IV in
the presence of gemiﬂoxacin, and DNA breakage mapped
at nucleotide levels by comigration on high-resolution
DNA sequencing gels against a ladder of dideoxy chain
termination products generated for the same PCR frag-
ment (results not shown). Cleavage occurred uniquely
between vector pCR2.1 TOPO nucleotides 3841T and
3842A (+1 position asterisked) in the sequence.
Figure 4. Comparison of Ca2+- and quinolone-mediated cleavage speciﬁcity by topo IV using the competitive assay. Mutant E-sites were mixed with
the wt site in equal amount (0.1 mg, determined by Nanodrop) and cleaved with topo IV in the absence () or presence of 32mM Ca2+ (Ca) or
320mM gemiﬂoxacin plus 6mM MgCl2 (Q). Reaction products were separated and analysed on 4–12% polyacrylamide gradient TBE gels as
described in the Figure 3 legend. Panels (A and E) show the control gemiﬂoxacin cleavage reactions in which the 276-, 256-, 236- and 216-bp
substrates each carried a wt E-site generating 176-, 156-, 136- and 116-bp products plus the common 100-bp partner. Drug-induced cleavage at the
E-site was 2- to 3-fold more efﬁcient than the Ca2+-mediated reaction, and therefore to facilitate comparison, only half of the reaction products from
each gemiﬂoxacin assay was loaded for comparison in Panels (B–D, F–H).
Figure 5. Drug structure-speciﬁc preferences at+1. Symmetric+1/+4 mutant E-sites were mixed with the wt site (+1G/+4T), cleaved with topo IV in
the presence of gemiﬂoxacin and levoﬂoxacin at the concentrations shown, and the products were separated and analysed on 4–12% polyacrylamide
gradient TBE gels as described in the Figure 3 legend. A 100-bp cleavage product is generated by breakage at any cleavable E-site.
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50 GGAT *AACC GTAT, which is also present in
pBR322 (nt 2431) and other ColE1/pMB1-based vectors.
Despite its different provenance, the V-site is closely hom-
ologous to the E-site, retaining the important 2A/+6T
bases, the presence of purine bases at+1 positions, A and
C bases at+2 and+3 positions and half-site conservation
of preferred 4G and 1T. Discovery of the V-site
allowed functional determinants to be examined in a
different sequence background.
Shared determinants in cleavage at E- and V-sites
To compare topo IV action at E- and V-sites, we used
linear pEA1 plasmid substrates bearing mutations at one
or both sites in the presence of either 6mM MgCl2
and gemiﬂoxacin, or 32 mM Ca2+ ions (Figure 6). In the
absence of drug or Ca2+, there was no topo IV-induced
plasmid breakage (lanes 1–4). Inclusion of gemiﬂoxacin
promoted cleavage at a spectrum of sites, and as
expected substitution of guanines at 4 with disfavoured
cytosines abrogated gemiﬂoxacin-stimulated cleavage at
the E-site eliminating the E1 and E2 products (Figure 6,
cf lanes 5 and 6). Introduction of 4C mutations or 2T
changes on both strands of the V-site blocked cleavage at
the site indicated by the absence of V1 and V2 products (cf
lanes 5, 7 and 8). Calcium ions (substituted for quinolone
and Mg2+) also induced plasmid cleavage by topo IV but
with differences in the spectrum of sites compared with
that seen with gemiﬂoxacin (Figure 5, cf lanes 5 and 9).
E- and V-sites were both cleaved in the presence of Ca2+
and the same mutations at 2 and 4 positions that
blocked drug-dependent DNA breakage (lanes 5–8) also
inhibited Ca2+-promoted DNA scission (lanes 9–12).
Blockade was not reversed by using supercoiled pEA1 as
substrate (results not shown). Similar to quinolone
cleavage, Ca2+ cleavage reactions were reversed by
EDTA, salt and heat (results not shown). Overall, the
results indicate that key determinants of quinolone and
Ca2+ cleavage uncovered at the E-site also apply to the
V-site validating the functional rules (Figure 3).
Non-cleavable E-sites bind topo IV
It is remarkable that many mutant E-sites were refractory
to DNA cleavage even at high drug concentrations
(Figure 3). To examine whether cleavage inhibiting muta-
tions act to prevent binding of topo IV to its 34-bp
binding site on DNA (33), we tested short 34-mer oligo-
nucleotide duplexes comprising wt or mutant E-sites as
inhibitors of topo IV-mediated cleavage of plasmid
pBR322 (Figure 7). Cleavage of supercoiled pBR322 was
efﬁcient even at low gemiﬂoxacin levels (0.17 mM),
producing linear and nicked DNA (Figure 7, lane B),
reﬂecting the 16-fold greater afﬁnity of topo IV for super-
coiled DNA over linear DNA (33) and the inherently
greater sensitivity whereby each cleavage event produces
linear DNA. Inclusion of increasing amounts of wt E-site
duplex decreased topo IV cleavage in a dose-dependent
manner (lanes 1–5) with almost complete inhibition at
30 mM (lane 5). Mutant E-sites M2C, M4C or M1A, in-
trinsically resistant to cleavage through 2C/+6G, 4C/
+8G or 1A/+5T mutations (Figure 3C), all inhibited
pBR322 cleavage with essentially the same efﬁciency as
the wt site yielding an estimated IC50 of 6–12 mM (lanes
6–20). Evidently, the mutant sites bind topo IV as
efﬁciently as the wt E-site, a result that has important
mechanistic implications.
Figure 6. Gate mutations at E- and V-sites inhibit topo IV cleavage. ScaI-linearized plasmid pEA1 bearing wt or mutant E- and V-sites was
incubated with topo IV alone (lanes 1–4) or in the presence of 2.5 mM gemiﬂoxacin (lanes 5–8) or 32mM Ca2+ (lanes 9–12). DNA cleavage was
induced as described in previous ﬁgure legends and DNA products were examined by electrophoresis in a 1% agarose gel. Cleavage fragments V1
and V2, and E1 and E2, arising from breakage at the V- and E-sites are indicated by arrows. The presence of wt or mutant sites is indicated above
each lane: 4C and 2T denote the presence of pairwise 4C/+8G or 2T/+6T mutations, respectively. M, DNA size markers.
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DISCUSSION
We have established the functional determinants govern-
ing DNA cleavage by topo IV and gyrase, the ﬁrst
comprehensive analysis for these bacterial type II topo-
isomerases. By site-directed mutagenesis of the chromo-
somal E-site and of the plasmid V-site, we deﬁned the
overlapping but distinct sequence requirements for
quinolone-promoted cleavage by gyrase and topo IV, the
features of an ‘optimal site’ and the contributions of
enzyme and drug to site selectivity deﬁned through
parallel studies of Ca2+-promoted DNA breakage. Using
these results and insights from X-ray crystal structures, we
suggest a plausible model for DNA selectivity by type II
enzymes.
Previous studies of topo IV and gyrase have provided
only limited biochemical data on quinolone-promoted
DNA cleavage speciﬁcity (20,21,33). We used system-
atic mutagenesis to investigate breakage at the E-site
(Figure 2) chosen for its strong cleavage by S. pneumoniae
topo IV (and, less efﬁciently, by gyrase) (23) and for which
we have determined recent X-ray crystal structures of topo
IV–E-site cleavage complexes (27,28). To examine up to
25 mutant sites, we developed a novel cleavage assay in
which wt and mutant E-sites are mixed together, cleaved
and the signature products are separated and analysed by
gel electrophoresis. The method provides a simple visual
display of base selectivity at each position (Figure 3). For
gemiﬂoxacin-induced DNA cleavage by topo IV, any
pairwise mutation of the symmetric 4G/+8C, 2A/+6T
and 1T/+5A abrogated or reduced DNA scission (as did
asymmetric single mutations at 4 or 2 positions,
Supplementary Figure S5). There was also selectivity at
3, +1 and +2 positions with the 3 positions showing
the greatest sequence tolerance. Strictly speaking, the
results relate to the E-site but we note the validity of key
preferences was conﬁrmed in the different sequence context
of the V-site (Figure 6). Assuming position-speciﬁc prefer-
ences act independently, the data deﬁne a set of functional
requirements for gemiﬂoxacin-promoted cleavage by
topo IV, namely G(N/a)A(T/a)*(Pu/py)(A/c)(C/g)(Py/pu)
(A/t)T(N/t)C (strongly preferred bases in bold capitals;
preferred bases in capitals; strongly disfavoured bases are
in lower case font; N indicates no strong preference;
Pu, purine; Py, pyrimidine; asterisk indicates DNA
scission between 1 and+1 bases). These functional rules
differ from those of gyrase 50GTAT *cNNg ATAC
(Supplementary Figure S2) [consensus GN4G(G/c)(A/c)G
*GNNCtTN(C/a) (23)] and contrast with the simple rec-
ognition sequences of many restriction enzymes, perhaps
reﬂecting the inherently greater complexity of operating
and arresting a reversible DNA gate.
Several important insights emerge from the mutational
analysis. First, the functional rules for gemiﬂoxacin-
induced breakage were much more stringent and showed
key differences compared with the topo IV consensus
G(G/c)(A/t)a*GNNCt(T/a)N(C/a) determined on
pneumococcal DNA using gemiﬂoxacin (23). Whereas
statistically favoured or disfavoured bases at the 4, 2
and 1 positions correctly predicted outcomes, surpris-
ingly sites with ‘neutral’ bases were also poorly cleaved
viz A/T, C/G at 4/+8, 2G/+6C, 1G/+5C and most
combinations at +2/+3 (Table 1, Figure 3C). There also
were differences in 3/+7 outcomes. Perhaps through
sequence bias or inclusion of weak sites, consensus data
need not predict biochemical outcome. Second, a variety
of single mutations blocked cleavage, suggesting many in-
dividual elements are crucial for DNA scission (Figure 3).
Third, the quinolone contributes to DNA selectivity
(Figure 4 and 5). Fourth, the E sequence is highly
optimized for cleavage, most mutations reduced cleavage
(Figure 3). Interestingly, loss of E- and V-sites did not
affect plasmid recovery or topology maybe due to com-
pensation by other sites (results not shown).
Analysis of Ca2+-promoted cleavage by topo IV
allowed us to establish the determinants for intrinsic
DNA recognition of a cleavage site by topo IV, namely
Figure 7. Mutant E-sites bind and inhibit topo IV. Supercoiled pBR322 DNA (400 ng) was incubated with topo IV and 0.17mM gemiﬂoxacin in the
absence (lane B) or presence of 34-mer DNA duplexes comprising the E-site sequence (wt) or mutant sites M2C, M4C or M1A bearing 2C/+6G,
4C/+8G and 1A/+5T alterations, respectively (lanes 1–20). For each set of lanes 1–5, 6–10, 11–15 and 16–20, the concentrations of 34-mer were
1.5, 3, 6, 12 and 30 mM, respectively. Cleavage conditions were as described in Figure 3. After SDS and proteinase K treatment, plasmid DNA
products were separated and displayed by gel electrophoresis in 1% agarose. Lane SC, supercoiled pBR322 substrate; lane A, as lane B but omitting
gemiﬂoxacin. N, L and SC denote nicked, linear and supercoiled plasmid bands.
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G(N/a)A(N/a) *CACG (N/t)T(N/t)C (Figure 4 and
Supplementary Figure S3). Comparison with gemiﬂoxacin
cleavage indicated that invariant base preferences at 4 to
1 on each strand are conferred primarily by the enzyme,
whereas the drug contributes to speciﬁcity at +1/+4 and
+2/+3 (Figures 4 and 5). Preferred bases map to key inter-
actions in the quinolone-E-site cleavage complex of
pneumococcal topo IV (27,28) wherein the gate DNA is
sharply bent into a U-shape and cleaved with a drug
molecule inserted between 1 and +1 bases on each
strand (Figure 8). The bicyclic ring system of the quin-
olone (Figure 1) is stacked against the tyrosyl-linked +1
base, preventing reversal by distancing the reactive 50
phosphotyrosine and 30-OH DNA ends (Figure 8).
Quinolones bind poly(dG) > poly(dA) > poly(dT) >
poly(dC) (34) with the greater preferences for purines
likely accruing through greater base stacking via p–p
interactions with the aromatic system of the drug, explain-
ing the+1 purine preference (Figures 3–5). The ParC I170
residues intercalate symmetrically from the minor groove
between the +8 and +9 bases on each strand (Figure 8)
(28) with the preferred 4G/+8C bases perhaps best
accommodating side-chain intercalation to induce DNA
bending. There is contact between the 3C of E-site
DNA and ParC R28 but no clashes with A at the 3
position on the other strand accounting for the 3 base
degeneracy. Surprisingly, no obvious enzyme contacts are
seen with the highly preferred 2A/+6T bases (or at+2/
+3 positions), but a ParE-chelated Mg2+ ion is bound to
the non-scissile phosphodiester group linking 1 and 2
nucleotides on each strand, which might be sensitive to the
bases present at these positions. Particular preferences at
+2/+3 may allow establishment of the pre-cleavage B-A-B
helix conformation at the gate (28) or facilitate adjust-
ments needed for drug–DNA intercalation. Evidently,
multiple enzyme, DNA, drug and metal ion interactions
are involved in stabilizing the bent and cleaved DNA gate.
At what stage is DNA selectivity conferred? To
approach this issue, we propose a model in which site-
speciﬁc DNA scission is the end product of sequential
enzyme–DNA binding, DNA bending, DNA breakage
and drug stabilization (Figure 9). Evidence for this
sequence of events comes from X-ray crystal structures
of different drug-free E-site complexes with topo IV (28)
[and in complexes of gyrase and topo II) (35–37)] in which
the DNA is bent and either cleaved or uncleaved, consist-
ent with the idea that enzyme-induced DNA bending
precedes DNA cleavage and drug arrest. That E-site
mutations did not affect binding to topo IV indicates
that DNA discrimination occurs at a subsequent step
(Figure 7).
Elegant biophysical studies reported that human topo
IIalpha bound two unrelated ‘cleavable’ and ‘uncleavable’
DNA duplexes with similar afﬁnity (39) [(also seen for
yeast topo II in (40)]. However, only the cleavable DNA
formed a minority high FRET enzyme species suggested
to be a bent DNA–enzyme complex. On that basis, DNA
sequence discrimination by topo II was attributed to the
intrinsic ability of a DNA to undergo bending and distor-
tion before DNA breakage. Were this scenario to apply to
topo IV, then the E- and V-sites and their cleavable
mutants would constitute a repertoire of DNA sequences
Figure 8. A. DNA bending and molecular interactions in the quin-
olone–E-site cleavage complex of S. pneumoniae topo IV. Top panel
shows the 34-bp E-site DNA sequence highlighting the key positions
engaged in topo IV-DNA and levoﬂoxacin-DNA interactions. Bases in
the 4 to+8 region are shown in bold. Active site ParC tyrosines that
form a covalent 50 phosphate link at +1 are shown in pink,
intercalating quinolone–Mg2+ complexes (Q) and ParC isoleucine side
chains are in dark green and red, respectively, and Mg2+ ions are
shown in light green. Centre and bottom panels depict top and side
views of the E-site DNA present in the levoﬂoxacin–topo IV cleavage
complex showing the disposition of drug molecules and DNA- and
drug-chelated Mg2+ ions (centre) within the highly bent DNA. The
smaller darker green sphere on each ﬂuoroquinolone molecule corres-
ponds to ﬂuorine. Images were generated with First Glance in JMol
based on protein data bank entry 3RAE.
Figure 9. Tentative scheme showing the steps involved in drug-
promoted DNA cleavage by a type II topoisomerase. Following non-
speciﬁc DNA binding to the enzyme, DNA selectivity is exercised at
subsequent DNA bending, DNA breakage and/or cleavage stabilization
steps. The importance of DNA bending as a prerequisite for DNA
cleavage was also noted in a recent article accepted after the present
work was submitted (38).
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capable of bending/distortion, with cleavage-inhibiting
DNA mutations acting to block this conformational
transition.
Intrinsic DNA bendability could play a role in DNA
selectivity but may not be the sole determinant for topo IV
with evidence suggesting that ‘enzyme-induced’ DNA
bending and drug stabilization are important factors.
Thus, the E-site-topo IV structures reveal multiple
protein–DNA contacts stabilizing the bent DNA whose
alteration through mutation could prevent DNA
bending and subsequent cleavage. Indeed, enzyme
speciﬁc determinants (Figure 4) that differ for topo IV
and gyrase (Figure 3 and Supplementary Figure S2)
suggest that enzyme contacts are important. Failure to
form the bent-DNA enzyme precursor could account for
the mutational blockade of both drug- and calcium-
mediated cleavage (Figure 4). Secondly, evidence from
this work (Figures 4 and 5) and elsewhere indicates the
drug itself contributes to DNA discrimination through
preferred interactions at 1 and/or +1 positions
(22,25,41). Presumably, the enzyme binds non-speciﬁcally
to DNA, and the drug stabilizes a subset of cleavage sites
able to accommodate ligand binding allowing their detec-
tion as double-strand breaks. Further work will be needed
to delineate the exact contributions of DNA bending and
drug stabilization in DNA gate selection and thereby
understand the roles of topo IV and gyrase as selective
drug targets in vivo (42–45).
In summary, we have established the ﬁrst systematic
functional rules for sequence-selective DNA cleavage by
topo IV and gyrase, identiﬁed enzyme, DNA and drug
requirements at the gate and proposed a plausible model
for sequence discrimination. The work provides signiﬁcant
insights on type II topoisomerase inhibition by current
ﬂuoroquinolones and should aid further development of
novel topoisomerase-targeting therapeutics.
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